REBECCA GUGGEMOS BAKKER-ARKEMA
Pharmacy in Ann Arbor, MI
License number
Michigan 5302027072
Expiration Date
Jun 30, 2009
Category
Pharmacy
Type
CS - Pharmacist
Address
Address
Ann Arbor, MI 48105
Personal information
See more information about REBECCA GUGGEMOS BAKKER-ARKEMA at radaris.comName
Address
Phone
5619 Overbrook Dr, Ann Arbor, MI 48105
Professional information
Treatment Of Congestive Heart Failure
US Patent:
7192951, Mar 20, 2007
Filed:
Jun 16, 2005
Appl. No.:
11/154909
Inventors:
Rebecca Guggemos Bakker-Arkema - Ann Arbor MI, US
Milton Lethan Pressler - Saline MI, US
Milton Lethan Pressler - Saline MI, US
Assignee:
Astellas Pharma Inc.
International Classification:
A61K 31/55, A61K 31/34
US Classification:
514215, 514471
Abstract:
Combinations of diuretics and vasopressin antagonists are useful to slow and reverse the symptoms and process of congestive heart failure, to increase the excretion of water in the urine, and to decrease the excretion of sodium and potassium ions in urine. Preferred vasopressin antagonists have the formula.
Treatment Of Congestive Heart Failure
US Patent:
2003000, Jan 9, 2003
Filed:
May 9, 2002
Appl. No.:
10/129892
Inventors:
Rebecca Bakker-Arkema - Ann Arbor MI, US
Milton Pressler - Saline MI, US
Milton Pressler - Saline MI, US
International Classification:
A61K031/55, A61K031/34
US Classification:
514/215000, 514/471000
Abstract:
Combinations of diuretics and vasopressin antagonists are useful to slow and reverse the symptoms and process of congestive heart failure, to increase the excretion of water in the urine, and to decrease the excretion of sodium and potassium ions in urine. Preferred vasopressin antagonists have the formula (I) wherein R and Rare hydrogen or lower alkyl; R, R, and Rare hydrogen, halo, alkyl, alkoxy, and amino; and Ris hydrogen or phenyl, and a pharmaceutically acceptable salt thereof
Treatment Of Congestive Heart Failure
US Patent:
2004017, Sep 9, 2004
Filed:
Mar 12, 2004
Appl. No.:
10/799415
Inventors:
Rebecca Bakker-Arkema - Ann Arbor MI, US
Milton Pressler - Saline MI, US
Milton Pressler - Saline MI, US
International Classification:
A61K031/55
US Classification:
514/215000
Abstract:
Combinations of diuretics and vasopressin antagonists are useful to slow and reverse the symptoms and process of congestive heart failure, to increase the excretion of water in the urine, and to decrease the excretion of sodium and potassium ions in urine. Preferred vasopressin antagonists have the formula
wherein R and Rare hydrogen or lower alkyl; R, R, and Rare hydrogen, halo, alkyl, alkoxy, and amino; and Ris hydrogen or phenyl, and a pharmaceutically acceptable salt thereof.
Method For Treating Postoperative Ileus
US Patent:
6645959, Nov 11, 2003
Filed:
Apr 19, 2002
Appl. No.:
10/111274
Inventors:
Rebecca Guggemos Bakker-Arkema - Ann Arbor MI
Milton Lethan Pressler - Saline MI
Milton Lethan Pressler - Saline MI
Assignee:
Warner-Lambert Company - Morris Plains NJ
International Classification:
A61K 3155
US Classification:
514215, 514200, 514481, 514471
Abstract:
This invention is a method for preventing or treating postoperative ileus comprising administering a vasopressin antagonist such as a compound of Formula (1), where R , R , and R include hydrogen, halo, alkyl, and alkoxy; R and R are hydrogen or alkyl; R is hydrogen, phenyl, or substituted phenyl, and pharmaceutically acceptable salts thereof.
Method Of Lowering Crp And Reducing Systemic Inflammation
US Patent:
2004016, Aug 26, 2004
Filed:
Nov 13, 2003
Appl. No.:
10/712859
Inventors:
Rebecca Bakker-Arkema - Ann Arbor MI, US
Ok Hwang - Ann Arbor MI, US
Sotirios Karathanasis - Carmel IN, US
Diane MacDougall - Ann Arbor MI, US
Ok Hwang - Ann Arbor MI, US
Sotirios Karathanasis - Carmel IN, US
Diane MacDougall - Ann Arbor MI, US
International Classification:
A61K031/12, A61K031/10, A01N031/14
US Classification:
514/675000, 514/712000, 514/722000
Abstract:
Disclosed are methods of lowering plasma CRP levels, reducing systemic inflammation, and inhibiting proinflammatory cytokine induced CRP production by administering an effective amount of a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl, or a pharmaceutically acceptable salt of the substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl or a pharmaceutical composition comprising a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl.
Selective Manipulation Of Triglyceride, Hdl And Ldl Parameters With 6-(5-Carboxy-5-Methyl-Hexyloxy)-2,2-Dimethylhexanoic Acid Monocalcium Salt
US Patent:
2004022, Nov 18, 2004
Filed:
May 13, 2004
Appl. No.:
10/844879
Inventors:
Diane MacDougall - Ann Arbor MI, US
Rebecca Bakker-Arkema - Ann Arbor MI, US
Rebecca Bakker-Arkema - Ann Arbor MI, US
International Classification:
A61K031/19
US Classification:
514/574000
Abstract:
Methods for selectively modulating triglyceride, high-density lipoprotein, and low-density lipoprotein levels in a patient by administering a certain dose of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt are disclosed.